,,ii  #aafth ,,congress  #b;d ,session  
,s4 #cdgh  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,march #ab1    
#bjbj,mr4 ,durbin 7for himself1 ,mr4    
,alexander1 ,mrs4 ,murray1 ,mr4 ,romney1
 ,mr4 ,jones1 ,mr4 ,blunt1 ,ms4 ,smith1 
,ms4 ,baldwin1 ,mr4 ,reed1 ,ms4         
,klobuchar1 and ,mr4 ,blumenthal7       
introduced the following bill2 which was
 read twice and referred to the         
,committee on ,health1 ,education1      
,labor1 and ,pensions  ,a ,,bill  ,to   
require a report to assess1 evaluate1   
and address the dependence of the       
,united ,states on critical drugs and   
devices sourced or manufactured outside 
of the ,united ,states4  #a4 ,short     
title ,this ,act may be cited as the    
,commission on ,america's ,medical      
,security ,act4  #b4 ,national          
,academies report on ,america's medical 
product supply chain security  7a7 ,in  
general ,not later than #fj days after  
the date of enactment of this ,act1 the 
,secretary of ,health and ,human        

,services shall enter into an agreement 
with the ,national ,academies of        
,sciences1 ,engineering1 and ,medicine  
7referred to in this section as the     
,national ,academies7 to examine1 and1  
in a manner that does not compromise    
national security1 report on1 the       
security of the ,united ,states medical 
product supply chain4  7b7 ,purposes    
,the report developed under this section
 shall-- 7#a7 assess and evaluate the   
dependence of the ,united ,states1      
including the private commercial sector1
 ,states1 and the ,federal ,government1 
on critical drugs and devices that are  
sourced or manufactured outside of the  
,united ,states1 which may include an   
analysis of-- 7,a7 the supply chain of  
critical drugs and devices of greatest  
priority to providing health care2  7,b7
 any potential public health security or
 national security risks associated with
 reliance on critical drugs and devices 
sourced or manufactured outside of the  
,united ,states1 which may include      

responses to previous or existing       
shortages or public health emergencies1 
such as infectious disease outbreaks1   
bioterror attacks1 and other public     
health threats2  7,c7 any existing      
supply chain information gaps1 as       
applicable2 and  7,d7 potential economic
 impact of increased domestic           
manufacturing2 and  7#b7 provide        
recommendations1 which may include a    
plan to improve the resiliency of the   
supply chain for critical drugs and     
devices as described in paragraph 7#a71 
and to address any supply               
vulnerabilities or potential disruptions
 of such products that would            
significantly affect or pose a threat to
 public health security or national     
security1 as appropriate1 which may     
include strategies to-- 7,a7 promote    
supply chain redundancy and contingency 
planning2  7,b7 encourage domestic      
manufacturing1 including consideration  
of economic impacts1 if any2  7,c7      
improve supply chain information gaps2  

7,d7 improve planning considerations for
 medical product supply chain capacity  
during public health emergencies2 and   
7,e7 promote the accessibility of such  
drugs and devices4  7c7 ,input ,in      
conducting the study and developing the 
report under subsection 7b71 the        
,national ,academies shall-- 7#a7       
consider input from the ,department of  
,health and ,human ,services1 the       
,department of ,homeland ,security1 the 
,department of ,defense1 the ,department
 of ,commerce1 the ,department of       
,state1 the ,department of ,veterans    
,affairs1 the ,department of ,justice1  
and any other ,federal agencies as      
appropriate2 and  7#b7 consult with     
relevant stakeholders1 which may include
 conducting public meetings and other   
forms of engagement1 as appropriate1    
with health care providers1 medical     
professional societies1 ,state-based    
societies1 public health experts1 ,state
 and local public health departments1   
,state medical boards1 patient groups1  

medical product manufacturers1 health   
care distributors1 wholesalers and group
 purchasing organizations1 pharmacists1 
and other entities with experience in   
health care and public health1 as       
appropriate4  7d7 ,definitions ,in this 
section1 the terms device and drug have 
the meanings given such terms in section
 #bja of the ,federal ,food1 ,drug1 and 
,cosmetic ,act 7#ba ,u4,s4,c4 #cba74